{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:36:16Z","timestamp":1786649776879,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"\n Purpose:<\/jats:title>\n The main objective of this study is to explore the efficacy of olopatadine 0.1% treatment in the resolution of symptoms of vernal keratoconjunctivitis (VKC) among the Indian population.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n This single-center, prospective cohort study involved 234 patients with VKC. Patients were treated with olopatadine 0.1%, twice daily for a period of 12 weeks and then followed up in 1\n st<\/jats:sup>\n week, 4\n th<\/jats:sup>\n week, 3\n rd<\/jats:sup>\n month, and 6\n th<\/jats:sup>\n month. The extent of relief in the symptoms of VKC was measured using total ocular symptom score (TOSS) and ocular surface disease index (OSDI).\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n In the present study, the dropout rate was 5.6%. Total of 136 males and 85 females with a mean age of 37.68 \u00b1 11.35 years completed the study. TOSS score reduced from 58.85 to 5.06 and the OSDI score reduced from 75.41 to 11.2 with statistical significance (\n P<\/jats:italic>\n < 0.01) from 1\n st<\/jats:sup>\n week to 6\n th<\/jats:sup>\n week after olopatadine 0.1% treatment. The data showed relief in subjective symptoms of itching, tearing, and redness, and relief in discomfort in functions related to ocular grittiness, visuals like reading, and environmental like tolerability in dry conditions. Further, olopatadine 0.1% was effective in both males and females, and patients across ages 18\u201370 years.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Based on TOSS and OSDI scores, the findings of this study validate safety and tolerability as revealed by low adverse effects and moderate efficacy of olopatadine 0.1% in reducing VKC symptoms in a broader age group (18\u201370 years) of both genders.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2048_22","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T03:29:44Z","timestamp":1684294184000},"page":"1822-1827","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of the efficacy of olopatadine 0.1% in the treatment of vernal keratoconjunctivitis in terms of clinical improvement based on total ocular symptom score and ocular surface disease index"],"prefix":"10.4103","volume":"71","author":[{"given":"S","family":"Mohan","sequence":"first","affiliation":[{"name":"Command Hospital Airforce, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Command Hospital Airforce, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Pawan","family":"Kumar","sequence":"additional","affiliation":[{"name":"Command Hospital Airforce, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Maheswari","sequence":"additional","affiliation":[{"name":"Command Hospital Airforce, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agrima","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Command Hospital Airforce, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Sagar","sequence":"additional","affiliation":[{"name":"Command Hospital Airforce, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"R1-20251006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/187221311794474883","article-title":"Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis","volume":"5","author":"Mishra","year":"2011","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40123-013-0019-y","article-title":"Management of vernal keratoconjunctivitis","volume":"2","author":"Leonardi","year":"2013","journal-title":"Ophthalmol Ther"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1350-9462(02)00006-X","article-title":"Vernal keratoconjunctivitis:Pathogenesis and treatment","volume":"21","author":"Leonardi","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"R5-20251006","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ajo.2012.11.018","article-title":"Vernal keratoconjunctivitis-like disease in adults","volume":"155","author":"Leonardi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R6-20251006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/bjophthalmol-2011-301376","article-title":"Vernal keratoconjunctivitis:An update","volume":"97","author":"Smedt","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1824-7288-39-18","article-title":"Allergic conjunctivitis:A comprehensive review of the literature","volume":"39","author":"Rosa","year":"2013","journal-title":"Ital J Pediatr"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","article-title":"Clnical grading of vernal keratoconjunctivitis","volume":"7","author":"Bonini","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/all.13334","article-title":"Clinical implications of mast cell involvement in allergic conjunctivitis","volume":"73","author":"Elieh Ali Komi","year":"2018","journal-title":"Allergy"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/2040622315612745","article-title":"Ocular itch associated with allergic conjunctivitis:Latest evidence and clinical management","volume":"7","author":"Ackerman","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"372","DOI":"10.18502\/jovr.v15i3.7456","article-title":"Conjunctivitis:A systematic review","volume":"15","author":"Azari","year":"2020","journal-title":"J Ophthalmic Vis Res"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4103\/0301-4738.119431","article-title":"Demographic and clinical profile of vernal keratoconjunctivitis at a tertiary eye care center in India","volume":"61","author":"Saboo","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ACI.0000000000000202","article-title":"Corneal complications of vernal keratoconjunctivitis","volume":"15","author":"Solomon","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R14-20251006","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/09273948.2016.1158282","article-title":"Topical olopatadine in the treatment of allergic conjunctivitis:A systematic review and meta-analysis","volume":"25","author":"Kam","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1185\/030079905X56547","article-title":"Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution:A review of pre-clinical and clinical research","volume":"21","author":"Rosenwasser","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/ijp.IJP_174_20","article-title":"To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital","volume":"52","author":"Sruthi","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"R17-20251006","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0011-393X(04)90032-X","article-title":"Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis","volume":"65","author":"Ciprandi","year":"2004","journal-title":"Curr Ther Res Clin Exp"},{"key":"R18-20251006","first-page":"976","article-title":"Demographic and clinical profile of vernal keratoconjunctivitis in teaching hospital, Kurnool","volume":"8","author":"Radhika","year":"2021","journal-title":"Int J Ion Mobil Spectrom"},{"key":"R19-20251006","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","article-title":"Vernal keratoconjunctivitis:A major review","volume":"87","author":"Kumar","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R20-20251006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.32553\/ijmbs.v3i8.464","article-title":"Clinical profile of patients with vernal keratoconjunctivitis","volume":"3","author":"Minhas","year":"2019","journal-title":"Int J Med Biomed Stud"},{"key":"R21-20251006","doi-asserted-by":"crossref","first-page":"15070","DOI":"10.14260\/jemds\/2015\/2138","article-title":"Vernal keratoconjunctivitis in school children in North Bangalore:An epidemiological and clinical evaluation","volume":"4","author":"Ashwini","year":"2015","journal-title":"J Evol Med Dent Sci"},{"key":"R22-20251006","doi-asserted-by":"crossref","first-page":"23","DOI":"10.33545\/26638266.2021.v3.i1a.58","article-title":"A comparative study of efficacy, tolerability and safety of 0.03% tacrolimus eye ointment and 0.05% cyclosporin eye drops in the treatment of vernal keratoconjunctivitis","volume":"3","author":"Padmini","year":"2021","journal-title":"Int J Med Ophthalmol"},{"key":"R23-20251006","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/ijo.IJO_2083_20","article-title":"Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis","volume":"69","author":"Ayyappanavar","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R24-20251006","first-page":"422","article-title":"Loteprednol etabonate ophthalmic suspension 0.2% (ALREX\u00ae) and olopatadine hydrochloride ophthalmic solution 0.1% (PATANOL\u00ae) in the treatment of allergic conjunctivitis","volume":"49","author":"Koo","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20251006","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3923\/ijp.2019.327.335","article-title":"Comparing efficacy and safety of olopatadine and emedastine in patients with allergic conjunctivitis","volume":"15","author":"Cao","year":"2019","journal-title":"Int J Pharmacol"},{"key":"R26-20251006","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/jop.2005.21.400","article-title":"Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density","volume":"21","author":"\u00c7orum","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"R27-20251006","doi-asserted-by":"crossref","first-page":"706","DOI":"10.18203\/2319-2003.ijbcp20201743","article-title":"A prospective comparative study to evaluate the efficacy and safety of olopatadine eye drops and bepotastine eye drops in subjects of vernal kerato conjunctivitis","volume":"9","author":"Malahat","year":"2020","journal-title":"Int J Basic Clin Pharmacol"},{"key":"R28-20251006","first-page":"488","article-title":"Topical use of olopatadine and cyclosporine a in treatment of vernal keratoconjunctivitis","volume":"7","author":"Knatova","year":"2014","journal-title":"J Clin Anal Med"},{"key":"R29-20251006","doi-asserted-by":"crossref","first-page":"785","DOI":"10.18203\/2319-2003.ijbcp20212373","article-title":"A comparative study of azelastine, cromolyn and olopatadine ophthalmic solution in vernal keratoconjunctivitis in a tertiary care hospital-open label parallel group study design","volume":"10","author":"Sharma","year":"2021","journal-title":"Int J Basic Clin Pharmacol"},{"key":"R30-20251006","first-page":"37","article-title":"A randomized controlled trail on the efficacy of topical olopatadine hydrochloride 0.1% and ketotifen fumarate 0.025% for the relief of symptoms of vernal keratoconjunctivitis","volume":"31","author":"Ali","year":"2020","journal-title":"Med Forum Mon"},{"key":"R31-20251006","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.18203\/2320-6012.ijrms20204230","article-title":"Comparison of two ophthalmic solutions of olopatadine hydrochloride (0.1%) and epinastine hydrochloride (0.05%) on clinical signs of vernal keratoconjunctivitis and side effects of the two drugs","volume":"8","author":"Ansari","year":"2020","journal-title":"Int J Res Med Sci"},{"key":"R32-20251006","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0149-2918(02)80007-8","article-title":"Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model","volume":"24","author":"Berdy","year":"2002","journal-title":"Clin Ther"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2048_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:18Z","timestamp":1786647498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2048_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2048_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-08-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}